

**Mental Health Medication Advisory Committee
Meeting Agenda, Open Session
July 11, 2023 2:30pm-4:30pm
Meeting Location*:**

*Due to COVID-19, this meeting will be held virtually. Please use the information below to join the meeting:
Computer Audio Enabled Zoom Meeting: Link:

<https://us02web.zoom.us/j/86476976937?pwd=Rm9GajlRVEJocnZRSEExGdWRlVkd1dz09>

Required Passcode: 471129 Audio Dial in: +1 312 626 6799 US Toll-free Meeting ID: 864 7697 6937

Members of the public are required to complete a conflict of interest form if they intend to provide public comments to the Board. To assist the operator in coordinating public comment, completed forms are due one week prior to the meeting (July 4, 2023). Please email the completed form to Annette.Grant@ks.gov.

COI Form link: <https://www.kdhe.ks.gov/DocumentCenter/View/465/Conflict-of-Interest-Form-PDF>

Committee Members

DeAnn Jenkins, MD (Chair)
Rachna Kalia, MD, FAPA
Rebecca Klingler, MD
Elizabeth Gant, APRN, PMHNP-BC

Charles Millhuff, DO
Karen Moeller, PharmD, BCPP
William Warnes, MD
Jill Reynoldson, PharmD, BCPP

KDHE Staff

Annette Grant, RPh
Victor Nguyen, PharmD
Anh Rongish, PharmD, BCPS

Sridevi Donepudi, MD, MMM, FAAFP
Crystal Blackmon, Sr. Administrative Assistant

MCO Staff

Angie Yoo, PharmD, Sunflower State Health Plan
Diane Buckingham, MD, Sunflower State Health Plan
Mark DeMary, PharmD, Aetna Better Health of Kansas
Ahmed Maher, MD, Aetna Better Health of Kansas
Kelly Flannigan, PharmD, United Healthcare Community Plan
Coleman Wheeler, MD, United Healthcare Community Plan

I. Call to Order

A. Announcements

II. Old Business

A. Review and Approval of April 18, 2023 Meeting Minutes
a. Committee Discussion

- B. Review of public comments from Madison Elliott (NAMI) (from previous meeting)
 - a. Public Comment
 - b. Committee Discussion
- C. Review of 24-hour PA Request Turn-Around-Time Report
 - a. Public Comment
 - b. Committee Discussion
- D. Provider Education Initiative - **Update**
 - Non-MH specialist provider continuing education document, for more appropriate mental health drug prescribing. Also, Pro-DUR and Retro-DUR educational requirements by CMS.
 - a. Public Comment
 - b. Committee Discussion
- E. Identification of Outlier Prescribers
 - Review of previously determined criteria for this analysis.
 - a. Previous Criteria
 - b. Public Comment
 - c. Committee Discussion

III. New Business

- A. ADHD Medications – Safe Use for All Ages
 - Minor revision to length of approval.
 - a. Prior Authorization Criteria
 - b. Public Comment
 - c. Committee Discussion
- B. Antidepressant Medications – Safe Use for All Ages
 - Minor revision to length of approval. Discussion on venlafaxine dosing.
 - a. Prior Authorization Criteria
 - b. Public Comment
 - c. Committee Discussion
- C. Antipsychotic Medications – Safe Use for All Ages
 - Minor revision to length of approval. Review of step-therapy for Lybalvi.
 - a. Prior Authorization Criteria
 - b. Public Comment
 - c. Committee Discussion
- F. Pharmaceutical Grade Melatonin
 - Product Review.
 - a. Public Comment
 - b. Committee Discussion

- IV. Stakeholder Input/Open Public Comment
 - A. Must submit a COI form

- V. Adjourn

**The next MHMAC meeting date is scheduled for October 10, 2023.
THIS AGENDA IS SUBJECT TO CHANGE**